tirzepatide and arthritis TOGETHER-PsA:Tirzepatide + Ixekizumab Rapidly Improves PsA Disease Control With Obesity/Overweight How Could GLP-1 Agonists Help

placebo preserved 5.5% additional weight loss at 88 weeks Typical taper window / 8 to 16 weeks of stepwise dose reduction before full stop Switching GLP-1s / direct substitution on the same injection day is generally well tolerated per clinical practice guidelines Long-term therapy indication / AACE guidelines classify obesity as a chronic disease requiring ongoing treatment Cardiovascular benefit / SELECT trial showed 20% MACE reduction with semaglutide 2.4 mg over 34.2 months Why stopping a GLP-1 abruptly almost always triggers weight regain Abrupt discontinuation of a GLP-1 receptor agonist removes a pharmacological brake on appetite, gastric emptying, and reward-pathway signaling all at once

Weight management needs can vary from person to person, which is why InjectCo begins every journey with a personalized online evaluation

& Haghpanah, S

As Mounjaro improves glycaemic control and reduces blood sugar fluctuations, some individualsparticularly those with previously poorly controlled diabetesmay experience what feels like relative hypoglycaemia even when blood glucose remains within the normal range